Cargando…

Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems

Background. Innovative drugs targeting the PD1/PD-L1 axis have opened promising scenarios in modern cancer therapy. Plenty of assays and scoring systems have been developed for the evaluation of PD-L1 immunohistochemical expression, so far considered the most reliable therapeutic predictive marker....

Descripción completa

Detalles Bibliográficos
Autores principales: Marletta, Stefano, Fusco, Nicola, Munari, Enrico, Luchini, Claudio, Cimadamore, Alessia, Brunelli, Matteo, Querzoli, Giulia, Martini, Maurizio, Vigliar, Elena, Colombari, Romano, Girolami, Ilaria, Pagni, Fabio, Eccher, Albino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321150/
https://www.ncbi.nlm.nih.gov/pubmed/35887569
http://dx.doi.org/10.3390/jpm12071073
_version_ 1784755968158990336
author Marletta, Stefano
Fusco, Nicola
Munari, Enrico
Luchini, Claudio
Cimadamore, Alessia
Brunelli, Matteo
Querzoli, Giulia
Martini, Maurizio
Vigliar, Elena
Colombari, Romano
Girolami, Ilaria
Pagni, Fabio
Eccher, Albino
author_facet Marletta, Stefano
Fusco, Nicola
Munari, Enrico
Luchini, Claudio
Cimadamore, Alessia
Brunelli, Matteo
Querzoli, Giulia
Martini, Maurizio
Vigliar, Elena
Colombari, Romano
Girolami, Ilaria
Pagni, Fabio
Eccher, Albino
author_sort Marletta, Stefano
collection PubMed
description Background. Innovative drugs targeting the PD1/PD-L1 axis have opened promising scenarios in modern cancer therapy. Plenty of assays and scoring systems have been developed for the evaluation of PD-L1 immunohistochemical expression, so far considered the most reliable therapeutic predictive marker. Methods. By gathering the opinion of acknowledged experts in dedicated fields of pathology, we sought to update the currently available evidence on PD-L1 assessment in various types of tumors. Results. Robust data were progressively collected for several anatomic districts and leading international agencies to approve specific protocols: among these, TPS with 22C3, SP142 and SP263 clones in lung cancer; IC with SP142 antibody in breast, lung and urothelial tumors; and CPS with 22C3/SP263 assays in head and neck and urothelial carcinomas. On the other hand, for other malignancies, such as gastroenteric neoplasms, immunotherapy has been only recently introduced, often for particular histotypes, so specific guidelines are still lacking. Conclusions. PD-L1 immunohistochemical scoring is currently the basis for allowing many cancer patients to receive properly targeted therapies. While protocols supported by proven data are already available for many tumors, dedicated studies and clinical trials focusing on harmonization of the topic in other still only partially explored fields are surely yet advisable.
format Online
Article
Text
id pubmed-9321150
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93211502022-07-27 Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems Marletta, Stefano Fusco, Nicola Munari, Enrico Luchini, Claudio Cimadamore, Alessia Brunelli, Matteo Querzoli, Giulia Martini, Maurizio Vigliar, Elena Colombari, Romano Girolami, Ilaria Pagni, Fabio Eccher, Albino J Pers Med Review Background. Innovative drugs targeting the PD1/PD-L1 axis have opened promising scenarios in modern cancer therapy. Plenty of assays and scoring systems have been developed for the evaluation of PD-L1 immunohistochemical expression, so far considered the most reliable therapeutic predictive marker. Methods. By gathering the opinion of acknowledged experts in dedicated fields of pathology, we sought to update the currently available evidence on PD-L1 assessment in various types of tumors. Results. Robust data were progressively collected for several anatomic districts and leading international agencies to approve specific protocols: among these, TPS with 22C3, SP142 and SP263 clones in lung cancer; IC with SP142 antibody in breast, lung and urothelial tumors; and CPS with 22C3/SP263 assays in head and neck and urothelial carcinomas. On the other hand, for other malignancies, such as gastroenteric neoplasms, immunotherapy has been only recently introduced, often for particular histotypes, so specific guidelines are still lacking. Conclusions. PD-L1 immunohistochemical scoring is currently the basis for allowing many cancer patients to receive properly targeted therapies. While protocols supported by proven data are already available for many tumors, dedicated studies and clinical trials focusing on harmonization of the topic in other still only partially explored fields are surely yet advisable. MDPI 2022-06-29 /pmc/articles/PMC9321150/ /pubmed/35887569 http://dx.doi.org/10.3390/jpm12071073 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Marletta, Stefano
Fusco, Nicola
Munari, Enrico
Luchini, Claudio
Cimadamore, Alessia
Brunelli, Matteo
Querzoli, Giulia
Martini, Maurizio
Vigliar, Elena
Colombari, Romano
Girolami, Ilaria
Pagni, Fabio
Eccher, Albino
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems
title Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems
title_full Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems
title_fullStr Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems
title_full_unstemmed Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems
title_short Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems
title_sort atlas of pd-l1 for pathologists: indications, scores, diagnostic platforms and reporting systems
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321150/
https://www.ncbi.nlm.nih.gov/pubmed/35887569
http://dx.doi.org/10.3390/jpm12071073
work_keys_str_mv AT marlettastefano atlasofpdl1forpathologistsindicationsscoresdiagnosticplatformsandreportingsystems
AT fusconicola atlasofpdl1forpathologistsindicationsscoresdiagnosticplatformsandreportingsystems
AT munarienrico atlasofpdl1forpathologistsindicationsscoresdiagnosticplatformsandreportingsystems
AT luchiniclaudio atlasofpdl1forpathologistsindicationsscoresdiagnosticplatformsandreportingsystems
AT cimadamorealessia atlasofpdl1forpathologistsindicationsscoresdiagnosticplatformsandreportingsystems
AT brunellimatteo atlasofpdl1forpathologistsindicationsscoresdiagnosticplatformsandreportingsystems
AT querzoligiulia atlasofpdl1forpathologistsindicationsscoresdiagnosticplatformsandreportingsystems
AT martinimaurizio atlasofpdl1forpathologistsindicationsscoresdiagnosticplatformsandreportingsystems
AT vigliarelena atlasofpdl1forpathologistsindicationsscoresdiagnosticplatformsandreportingsystems
AT colombariromano atlasofpdl1forpathologistsindicationsscoresdiagnosticplatformsandreportingsystems
AT girolamiilaria atlasofpdl1forpathologistsindicationsscoresdiagnosticplatformsandreportingsystems
AT pagnifabio atlasofpdl1forpathologistsindicationsscoresdiagnosticplatformsandreportingsystems
AT eccheralbino atlasofpdl1forpathologistsindicationsscoresdiagnosticplatformsandreportingsystems